Building microbiological quality during the manufacture of medicines
25 min
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer/Oncology
-
9 min
-
18 min
2. Cancer vaccines- Dr. Elias Sayour
-
11 min
3. The future of blood tests in cancer treatment- Dr. Isaac Garcia-Murillas
-
15 min
-
14 min
5. Artificial intelligence in precision medicine- Dr. Michael P. Menden
-
18 min
6. How liver X receptor regulates intestinal regeneration and tumor growth- Dr. Srustidhar Das
- Neurology/Neuroscience
-
8 min
7. Integrated multimodal cell atlas of Alzheimer’s disease- Dr. Michael Hawrylycz
-
17 min
8. How and why neurons die in Alzheimer's disease?- Prof. Bart De Strooper
-
17 min
9. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD- Prof. Katrin Andreasson
-
18 min
10. Advancing ALS genetics through accessible testing- Dr. Teresa Fecteau
-
13 min
11. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
25 min
12. Translational research in amyotrophic lateral sclerosis (ALS)- Prof. Aaron D. Gitler
-
13. Muscarinic acetylcholine receptor modulation in neurological diseases- Prof. Andrew B. Tobin
- Immunology & Inflammation
-
14 min
14. Role of ETS2 in autoimmune and inflammatory diseases- Dr. James Lee
-
29 min
15. Rheumatic diseases and musculoskeletal pain- Prof. Anisur Rahman
-
16. Decoy-resistant IL18: how engineered E. coli enhances immune responses against tumors- Dr. Rizwan Romee
-
16 min
17. Transmembrane domains and the regulation of trogocytosis in T cells- Dr. Stefano Barbera
-
12 min
- Infectious Diseases/Microbiology
-
10 min
-
31 min
20. Elite controllers of HIV: from discovery to future therapies- Prof. Bruce Walker
-
8 min
-
23 min
22. Towards developing a universal influenza vaccine- Prof. Peter Palese
- Pharmaceutical Sciences
-
19 min
23. The state of the art in secondary pharmacology- Dr. Jean-Pierre Valentin
-
19 min
24. The safety, toxicology, and regulation of antibody-drug conjugates- Dr. Veysel Kayser
-
18 min
-
31 min
26. Management of generic drug development: challenges and opportunities- Mr. Sandeep Patil
-
30 min
27. Translational medicine: the risk of failure in delay and how to reduce it- Prof. Martin Wehling
-
13 min
28. The regulation of cell therapy- Prof. Moutih Rafei
-
31 min
29. Scale-up challenges in the production of nanomedicines from lab to industry- Prof. Dr. Oya Tagit
-
8 min
30. Challenges and solutions of scaling up- Dr. Shaukat Ali
-
11 min
-
14 min
32. Using real-world insights on drug interactions to inform drug development- Dr. Amita Datta-Mannan
-
50 min
33. Role of marketing authorization holder in drug safety- Dr. Raphael Elmadjian Pareschi
- Methods
-
21 min
34. The role of preregistration and registered reports in improving research transparency and reproducibility- Dr. Peter Bonde Ernst-Rasmussen
-
17 min
35. Decoding aging: how a proteomic clock predicts mortality and disease across populations- Dr. M. Austin Argentieri
-
10 min
36. MassBank development and future- Dr. Emma L. Schymanski
-
25 min
37. Synthetic whole embryo models and their applications- Prof. Jacob (Yaqub) Hanna
-
14 min
38. Pioneering proteomics: insights on advancements in the science of proteins- Prof. Ruedi Aebersold
Topics Covered
- The development of naked and drug-conjugated antibodies against endoglin and CD75b
- The results of recent clinical trials with both therapeutic antibodies
- Advantages and challenges in the development of naked and drug-conjugated antibodies
Biography
Ben K. Seon is a Professor of Immunology and Oncology. He is a nationally and internationally recognized cancer researcher whose main research has been on the development of unique monoclonal antibodies that define novel tumor associated antigens or novel epitopes of tumor associated antigens and application of these monoclonal antibodies and their immunoconjugates for cancer therapy. Recent focus of his studies has been on translational research in the fields of antibody-based anti-angiogenic and vascular targeting therapy of cancer by targeting endoglin (CD105), which he co-discovered.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Seon, B. (2020, September 16). The development of therapeutic antibodies against oncogenic antigens [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 4, 2026, from https://doi.org/10.69645/JYDV6418.Export Citation (RIS)
Publication History
- Published on September 16, 2020
Financial Disclosures
- Prof. Ben Seon has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
The development of therapeutic antibodies against oncogenic antigens
Published on September 16, 2020
15 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...